<P>&nbsp;</P> <P align=justify><STRONG>Calixar SAS, a Lyon based start-up providing services focused on <A title="" href="https://www.aderly.com/cosmetique-fashion-france/cosmetic-beauty-industry-dermocosmetology,p,63,EN.jsp" target=_blank>membrane proteins</A>, announced in July that it has completed an initial funding round in which it raised 875,000 Euros from private investors and business angels</STRONG>. The funds will enable Calixar to develop its international operations and move its research programs forward. It also means the company will be able to offer its clients even more targeted services, and give a broader client base easy access to its unique technology.</P> <P align=justify>&nbsp;</P> <P align=justify>Among the investors that took part in this financing are business angels from the <A title="" href="http://health-angels-ra.org/" target=_blank>Health-Angels Rh&#244;ne Alpes</A>:&nbsp; &#8220;<EM>We were attracted by the potential of Calixar&#8217;s technology and the know-how of its staff, which should enable them to surmount a major technological barrier facing research laboratories and ultimately develop more efficacious therapies</EM>,&#8221; said Fabrice Paublant, president of Health Angels Rh&#244;ne-Alpes. &#8220;<EM>Calixar recently signed several research agreements in Europe and the United States, and the funds it has now raised will enable it to expand its international activities</EM>.&#8221;</P> <P align=justify>&nbsp;</P> <P align=justify><STRONG>Calixar provides a comprehensive range of services focused exclusively on membrane proteins</STRONG> including: identification, production, extraction, purification, stabilization and crystallization. Now housed within the <A title="" href="http://www.ibcp.fr/" target=_blank>Institute of Biology and Protein Chemistry </A>at Claude Bernard University in Lyon (a research establishment run in conjunction with France&#8217;s National Scientific Research Centre &#8211; CNRS), the company currently employs nine people and expects to generate revenues of 350,000 euros in 2012.<BR></P>